CTSO · Cytosorbents Corporation — research history
Complete research history. Every dossier, draft, kill, publish, and lesson the system has produced on CTSO. Public so users can audit, AI can re-reference. Live price refreshes every 60s.
About CTSO · Cytosorbents Corporation
Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform in the United States, Germany, and internationally. Its flagship product, CytoSorb, is an extracorporeal blood purification cartridge to reduce cytokine storms in common critical illnesses, bilirubin in liver failure, myoglobin in trauma and critical illnesses, and inflammatory mediators and blood thinners in cardiac surgery applications, as well as to remove antithrombotic drugs and inflammatory mediators in cardiothoracic surgery applications. The company also develops DrugSorb-ATR antithrombotic removal system, an investigational device to reduce the severity of perioperative bleeding in high-risk surgery due to blood thinning drugs; ECOS-300CY to reduce cytokines and other inflammatory mediators when used in an ex vivo organ perfusion system; VetResQ, a broad-spectrum blood purification adsorber for the treatment of septic shock, toxic shock syndrome, toxin-mediated diseases, pancreatitis, trauma, liver failure, heat stroke, and lung injury in animals; and PuriFi, an advanced hemoperfusion pump for blood purification therapies. In addition, it develops HemoDefend-BGA, a blood purification technology platform to reduce anti-A and anti-B antibodies in plasma and whole blood. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.
Live Quote
SELL (score -5) · 12-1 mom -61.7% · RSI 43.2 · below_both · -66.7% from high
Targets blend Wall Street consensus (2 analysts: low $0.75 / mean $2.88 / high $5.00) with chart-derived floors and ceilings.
1-Year Chart · RSI · MACD
Research Timeline
Newest first. Each entry shows what stage produced it, the verdict/decision, and the reasoning.
Stage crashed before producing an artifact (e.g. LM Studio timeout, malformed JSON, network error). The cooldown will hold this off the queue for ~1h before retry.
CTSO is a nano-cap ($26M) medical device company with an FDA-rejected blood purification technology (DrugSorb-ATR). The stock has collapsed ~70% from its 52w high amid twin regulatory setbacks: the FDA denied the De Novo for DrugSorb-ATR twice and Health Canada refused approval, forcing resubmission. The company declared going concern in Q1 2026 with only ~$4.8M unrestricted cash vs. quarterly burn of $3-5M, and faces a Nasdaq minimum bid price delisting notice ($0.41 vs. required $1.00 by September 28, 2026). Revenue is flat (~2% growth to $37M annualized) while the company burns $10M+ annually in cash. No recent CEO/CFO open-market buys; insider cluster buying from January 2025 (~$450K via rights offering participation) represents stale conviction given the stock's subsequent collapse.
CytoSorbents is a micro-cap ($31M market cap) medical device company whose flagship CytoSorb blood purification cartridge treats life-threatening critical care and cardiac surgery conditions globally. The stock has collapsed ~49% YTD to near 52-week lows following two FDA De Novo denials for DrugSorb-ATR (April and August 2025), a new $29.3M debt obligation from a structured loan, and persistent operating losses with minimal revenue growth (~1.6%). The FDA proposed an expedited path in late January 2026 pre-sub meeting — but the company is still awaiting clarity on exact submission requirements before filing a new De Novo application. Q1 2026 results (reported May 13) showed modest revenue ($8.9M, +2% YoY) and continued EPS miss (-$0.08 vs -$0.055 est). CEO made one open-market purchase of $64K in November 2025 but no recent director-level cash buys. Options market is extremely illiquid with only two strikes available; IV on the ATM Aug expiry exceeds 234%. The regulatory binary and financial distress make this a speculative situation — not an income candidate given sub-$0.50 price and no dividend.